43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
1 citations
,
June 2025 in “Scientific Reports” Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
13 citations
,
July 2019 in “Journal of Dermatological Science” Increasing alkaline phosphatase in human skin cells helps to grow more hair.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
16 citations
,
September 2018 in “Journal of Molecular Liquids” The PS-b-PAA copolymer nanomicelles are effective for delivering a cancer treatment drug in photodynamic therapy.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
34 citations
,
July 1993 in “PubMed”
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
2 citations
,
April 2016 in “Más dermatología” The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” November 2025 in “Zenodo (CERN European Organization for Nuclear Research)”
1 citations
,
August 2021 in “Consilium Medicum” Selencin effectively reduces hair loss and improves hair health in diffuse alopecia.
8 citations
,
December 2007 in “Journal of Thoracic Oncology” Erlotinib can cause significant but temporary hair loss in lung cancer patients.
1 citations
,
January 2022 in “Rasayan journal of Chemistry” Albizia saponaria bark ethanol extract, particularly at 15%, promotes hair growth in rabbits.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
September 2003 in “Reactions Weekly” 8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
15 citations
,
October 2016 in “Steroids” Researchers developed a new method to find substances in herbs that can block a specific enzyme linked to hair loss.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.